---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-019017"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2022-12-28T23:59:59+00:00"
generated_at: "2026-06-20T22:23:27.057999+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ReShape Lifesciences completes 1-for-50 reverse stock split, authorized shares increased to 300M

## Summary
- Reverse stock split effective at trading open on December 23, 2022; each 50 shares become 1 share.
- Authorized common shares increased from 100M to 300M; no reduction in preferred or common authorized.
- Fractional shares rounded up to nearest whole share; proportional adjustments to warrants, options, preferred.
- Stockholders approved the reverse split and authorized share increase at annual meeting on December 14, 2022.
- Series D Mirroring Preferred Stock automatically terminated effective with the reverse split.

## SEC filing metadata
- accession: 0001558370-22-019017
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2022-12-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000155837022019017/0001558370-22-019017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000155837022019017/rsls-20221221x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-019017
- JSON: https://secwatch.observer/filing/0001558370-22-019017.json
- Plain text: https://secwatch.observer/filing/0001558370-22-019017.txt

## Key facts
- Governance Changes
  Vyome Holdings, Inc: Effected a 1-for-50 reverse stock split and increased authorized common stock from 100,000,000 to 300,000,000 shares (effective 2022-12-23).
  - Change: charter amendment
  - Effective: 2022-12-23
  source text: On December 21, 2022, ReShape Lifesciences Inc. (the "Company") filed a Certificate of Amendment (the "Certificate of Amendment") to its Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse split of the Company’s outstanding common stock, $0.001 par value per share (the "Reverse Stock Split"). The Reverse Stock Split became effective for trading purposes upon the commencement of trading on December 23, 2022, at which point the Company’s common stock began trading on a split adjusted basis on the Nasdaq Capital Market. As a result of the Reverse Stock Split, each 50 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. Any fractional shares of common stock resulting from the Reverse Stock Split will be rounded up to the nearest whole share. As a result of the Reverse Stock Split, proportional adjustments will be ma
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427570/000155837022019017/0001558370-22-019017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.